Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

NR5A1 (nuclear receptor subfamily 5, group A, member 1)

Written2014-09Carmen Ruggiero, Mabrouka Doghman, Enzo Lalli
Institut de Pharmacologie Moleculaire et Cellulaire CNRS, Valbonne 06560, France (CR, MD, EL); Associated International Laboratory (LIA) NEOGENEX CNRS, Valbonne 06560, France (CR, MD, EL); University of Nice-Sophia-Antipolis, Valbonne 06560, France (CR, MD, EL)

(Note : for Links provided by Atlas : click)

Identity

Alias_namesFTZF1
nuclear receptor subfamily 5
Alias_symbol (synonym)FTZ1
SF-1
ELP
AD4BP
hSF-1
Other aliasPOF7
SF1
SPGF8
SRXY3
HGNC (Hugo) NR5A1
LocusID (NCBI) 2516
Atlas_Id 45858
Location 9q33.3  [Link to chromosome band 9q33]
Location_base_pair Starts at 124481236 and ends at 124507420 bp from pter ( according to hg19-Feb_2009)  [Mapping NR5A1.png]
 
  Figure 1. NR5A1 chromosomal localization. The NR5A1 gene maps on chromosome 9q33.3 (adapted from GeneCards).
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
NR5A1 (9q33.3) / NR6A1 (9q33.3)
Note Steroidogenic factor-1 (SF-1) is an orphan member of the nuclear receptor superfamily which acts as a key regulator of adrenogonadal development and tissue-specific gene expression in steroidogenic cells. Parker's and Morohashi's groups identified SF-1 by its capacity to activate transcription from multiple P450 steroidogenic enzyme promoters (Lala et al., 1992; Morohashi et al., 1992). Besides its recognized role as a master regulator of steroidogenesis in the adrenal cortex and gonads, recent studies indicate that the regulation of gene expression in the adrenal cortex by SF-1 also involves processes other than steroidogenesis (reviewed in Lalli et al., 2013).

DNA/RNA

Note In 1992 the mouse Sf-1 gene (Nr5a1) was cloned from an adrenal cDNA library using a probe corresponding to the DNA-binding domain (DBD) of the related orphan receptor retinoid X receptor (Lala et al., 1992). Later, its bovine homologue (called adrenal 4-binding protein, Ad4BP) was identified from an adrenal cDNA library exploiting the partial sequence of a protein purified from bovine adrenal extracts (Honda et al., 1993). The proteins encoded by both these murine and bovine cDNAs were able to activate promoters of steroid hydroxylase enzymes, indicating that a common steroidogenic factor had been identified. Initially the mouse gene encoding SF-1 was called FtzF1, similar to the Drosophila orphan nuclear receptor fushi tarazu factor homolog 1 (FTZ-F1) and mapped to chromosome 2 (Ueda et al., 1990; Swift and Ashworth, 1995; Taketo et al., 1995). The corresponding human SF-1 gene was initially termed FTZF1 and later NR5A1 (see above) according to the standard nomenclature system for nuclear receptors.
Description Size: 26.18 Kb (GeneCards), 7 exons. mRNA: 3095 bp (NM_004959).
Transcription The human NR5A1 gene is mapped to the long arm of chromosome 9 (9q33, Figure 1) and consists of 7 exons spanning approximately 27 Kb of genomic DNA (Taketo et al., 1995; Oba et al., 1996; Wong et al., 1996). Exon 1 is untranslated.

Protein

 
  Figure 2. Structure of the SF-1 protein. SF-1 contains the major structural features present in all nuclear receptors. N, N-terminus of the protein; DBD, DNA binding domain with two zinc finger (ZnI and ZnII) motifs; Ftz-F1, Fushi-tarazu-F1 domain with a nuclear localization signal (NLS); Hinge, hinge region displaying a Pro-rich (proline-rich) region and an AF-1- (transcriptional activation domain 1) like domain; LBD, ligand-binding domain; AF-2, transcriptional activation domain 2; C, C-terminus of the protein.
Description The SF-1 protein contains the typical domains of other members of the nuclear receptor superfamily ( NURSA): an N-terminal DBD including two zinc fingers, a flexible proline-rich hinge region displaying AF-1 - like activation activity, a ligand binding domain (LBD) and a C-terminal AF-2 activation domain, which is required for transcriptional activity and cofactor interactions (Figure 2).
A proximal (P) box implicated in the specific recognition of DNA target sequences by nuclear receptors has been described in the first zinc finger of SF-1 DBD. This sequence interacts with the hormone response element core in the major groove of the DNA helix by recognizing variations on the AGGTCA motif (Evans, 1998). SF-1 also exhibits a FTZ-F1 box or A box, which represents a 30-aminoacid extension of the DBD, being important for DNA anchoring. Indeed, at variance from most nuclear receptors, SF-1 binds to target genes monomerically rather than as a homo- or heterodimer and with highest affinity to 5'YCAAGGYCR'3 (where Y= T/C; R= G/A) (Ueda and Hirose, 1991; Wilson et al., 1993). X-ray crystallography of the SF-1 DBD complexed with a sequence in the inhibin-α gene proximal promoter region has shown that the A-box primarily interacts with the 5' flanking sequence and the first part of the half site in the minor groove of DNA (Ito et al., 2000a; Little et al., 2006). Moreover, the same study revealed that SF-1 displays a helix in the C-terminal segment of the FTZ-F1 box which interacts with both the core DBD and the DNA, thus acting as an important determinant of the complex stability (Little et al., 2006). It has been proposed that this helix may also serve as a platform for coactivators and other DNA-bound factors interaction (Little et al., 2006).
The hinge region, which lies between the N-terminal DBD and the C-terminal LBD is more than a flexible connector between the LBD and the DBD. It participates in conjunction with helix 1 (H1, see below) to promote an active protein conformation (Desclozeaux et al., 2002). Furthermore, it is important for post-transcriptional/translational modifications, like phosphorylation and SUMOylation (Hammer et al., 1999; Komatsu et al., 2004; Lee et al., 2005; Lewis et al., 2008). In particular, phosphorylation of the hinge region enhances SF-1 overall stability and transcriptional activity (Desclozeaux et al., 2002).
The LBD contains 12 helices (H1-H12, like other nuclear receptors), that can form an AF2 domain for the recruitment of cofactors. SF-1 has been considered as an "orphan" nuclear receptor for many years because of the absence of high-affinity naturally occurring ligands identified. This led to the hypothesis that the LBD of SF-1 could adopt a stable conformation in the absence of ligand (Desclozeaux et al., 2002). Later, different groups have been able to crystallize the SF-1 LBD, showing that small phospholipids ligands (e.g. phosphatidylinositols) can bind to this domain (Krylova et al., 2005; Li et al., 2005; Wang et al., 2005).
Protein translation:
MDYSYDEDLD ELCPVCGDKV SGYHYGLLTC ESCKGFFKRT VQNNKHYTCT ESQSCKIDKT
QRKRCPFCRF QKCLTVGMRL EAVRADRMRG GRNKFGPMYK RDRALKQQKK AQIRANGFKL
ETGPPMGVPP PPPPAPDYVL PPSLHGPEPK GLAAGPPAGP LGDFGAPALP MAVPGAHGPL
AGYLYPAFPG RAIKSEYPEP YASPPQPGLP YGYPEPFSGG PNVPELILQL LQLEPDEDQV
RARILGCLQE PTKSRPDQPA AFGLLCRMAD QTFISIVDWA RRCMVFKELE VADQMTLLQN
CWSELLVFDH IYRQVQHGKE GSILLVTGQE VELTTVATQA GSLLHSLVLR AQELVLQLLA
LQLDRQEFVC LKFIILFSLD LKFLNNHILV KDAQEKANAA LLDYTLCHYP HCGDKFQQLL
LCLVEVRALS MQAKEYLYHK HLGNEMPRNN LLIEMLQAKQ T
Sequence length: 461 aa; Molecular weight: 51,636 kDa
Expression SF-1 localization in adult tissues has been widely investigated in mice, rats, human and other vertebrates. Its expression pattern is consistent with its role as a steroidogenesis master regulator and is strikingly overlapping with that of another nuclear receptor, Dax-1 (Nr0b1) (Ikeda et al., 1996; Swain et al., 1996; Tamai et al., 1996; Ikeda et al., 2001), which functions as a negative regulator of SF-1 activity. SF-1 is expressed in tissues involved in steroid hormone production and reproductive function, i.e. the three layers of the adrenal cortex, testicular Leydig and Sertoli cells, ovarian interstitium, theca and granulosa cells, and, to a lesser degree, corpus luteum (Honda et al., 1993; Ikeda et al., 1993; Morohashi et al., 1994; Ramayya et al., 1997; Morohashi, 1999). SF-1 is also expressed in non-steroidogenic tissues like pituitary gonadotropes. It is also expressed in the dorsomedial portion of the ventromedial hypothalamus (VMH) (Ikeda et al., 1994; Shinoda et al., 1995), in the endothelial linings of the venous sinuses and pulp veins in the spleen (Ramayya et al., 1997; Morohashi et al., 1999), and in a subset of hippocampal neurons. It has been described that in developing human embryos SF-1 represents the earliest marker of adrenogonadal differentiation, first appearing in the urogenital ridge (Ikeda et al., 1994; Morohashi et al., 1995; Hanley et al., 1999; Hanley et al., 2001).
In the mouse, SF-1 is first expressed at embryonic day 9 (E9.0) in the adrenal/gonadal primordium (AGP) (Hatano et al., 1996). After gonadal and adrenal anlagen separation at E11.0, SF-1 is expressed throughout gestation in the developing steroidogenic adrenal portion and in zona glomerulosa, fasciculata and reticularis of the adult gland. In contrast, it is not expressed in the neural crest cells that migrate to the medulla during development (Ikeda et al., 1994) nor in the adult medulla (Ikeda et al., 1993). While SF-1 is expressed in the indifferent gonad, it displays a sexually dimorphic expression pattern in the developing testis and ovaries (Ikeda et al., 1994). Indeed, it disappears from the ovaries between E13.5 to E16.5 and reappears at the beginning of folliculogenesis, being expressed in granulosa, thecal and luteal cells of the adult ovary (see above, Ikeda et al., 1993; Hanley et al., 1999; Hanley et al., 2001).
During embryonic development, SF-1 expression is tightly temporally and spatially controlled. An E-box-binding site within the basal promoter of SF-1 gene has been described to be critical for SF-1 expression (Nomura et al., 1995). The transcription factor POD1/capsulin has been reported to repress SF-1 expression in the gonad through binding to this E-box (Tamura et al., 2001; Cui et al., 2004), whereas WT1 plays a role as a positive regulator of SF-1 expression in the developing gonad (Wilhelm and Englert, 2002), like the LIM homeobox gene Lhx9 (Birk et al., 2000). Interestingly, genetic and molecular evidence shows that the transcription co-factor CITED2 interacts with WT1 to promote SF-1 expression in the AGP before the separation between gonad and adrenal cortex, a critical time during embryogenesis (Val et al., 2007).
Recently, Morohashi and collaborators have identified one intergenic and three intragenic (intronic) enhancers, which are essential for tissue and SF-1 stage specific expression in mice. Those tissue-specific enhancers direct SF-1 expression to the fetal adrenal (Fetal Adrenal Enhancer, fAdE, localized to intron 4) (Zubair et al., 2006), the developing pituitary and adult gonadotropes (Pituitary Gonadotrope Enhancer, PGE, localized to intron 6) (Shima et al., 2008), the developing diencephalon and adult VMH (VMH Enhancer, VMHE, localized to intron 6, upstream of PGE) (Shima et al., 2005) and fetal Leyding cells (Fetal Leydig cell Enhancer, FLE; intergenic, located upstream of the transcriptional start site) (Shima et al., 2012). Although the activity of these enhancers has been established only in mice, all enhancers, like the basal promoter, are conserved among the different animal species (Shima et al., 2012).
Localisation SF-1 is constitutively localized in the nucleus where it acts as a DNA-binding transcription factor. Interestingly, it has been described that it also moves inside the nucleus according to the status of its post-translational modifications (Chen et al., 2004; Fan et al., 2004). SUMOylation seems to repress SF-1 activity as the mutations of its SUMO acceptor sites K119 and K194 enhance SF-1 - driven gene activation. It has been proposed that SUMO-conjugated SF-1 localizes to the PML nuclear speckles, where SF-1 is sequestered from nucleoplasm and is associated with repressors, like DP103 (Lee et al., 2005; Wang et al., 2013). SF-1 can also be acetylated at the KQQKK sequence in the Ftz-F1 box and activated by the histone acetyltransferase p300 (Chen et al., 2005). Following cAMP stimulation, SF-1 spreads out into discrete transcriptionally active foci containing RNA polymerase II, p300 (Chen et al., 2005) and the ubiquitous histone acetyltransferase GCN5 (Fan et al., 2004). It has been hypothesised that SF-1 is recruited to those transcriptionally active loci as a result of physical interactions with co-regulators like p300 and GCN5. Furthermore, when SF-1 is acetylated by p300 at the FTZ-F1 domain, its binding to p300 increases. It seems that acetylation is involved in retaining SF-1 in the transcriptionally active nuclear foci, thus promoting SF-1 - mediated target gene transcription (Chen et al., 2005). Neither phosphorylation at Ser 203 (Hammer et al., 1999) nor ubiquitination (Chen et al., 2007) appear to change or affect SF-1 distribution. Recently, it has been shown that SF-1 is also located in the centrosome. Immunofluorescence analysis revealed that it colocalizes with the centrosome marker γ-tubulin in mouse adrenocortical Y1 and mouse testicular Leydig MA-10 cells (Lai et al., 2011). Sucrose gradient fractionation studies in Y1 cells have confirmed immunofluorescence results (Lai et al., 2011). A centrosome localization signal (CLS) has also been identified by deletion analysis and localized to aa 348-367 (Lai et al., 2011). Moreover, SF-1 centrosomal localization results to be independent from microtubule (MT) transportation, as after MT depolymerization SF-1 still colocalizes with acetylated tubulin (Wang et al., 2013).
Function SF-1 as a master regulator of gene expression in steroidogenic cells
SF-1 was identified as a key factor that regulates the expression of several steroidogenic enzymes in a tissue-specific manner (Lala et al., 1992; Morohashi et al., 1992). In steroidogenic tissues, SF-1 regulates steroidogenic pathways including genes encoding cytochrome P450 enzymes as CYP11A1 (Chau et al., 1997), CYP17A1 (Bakke et al., 1995), CYP21A2, CYP11B1 (Morohashi et al., 1993), CYP11B2 (Bassett et al., 2002), 3β-hydroxysteroid dehydrogenase (3βHSD) (Leers-Sucheta et al., 1997), steroidogenic acute regulatory protein (StAR) (Sugawara et al., 1996). Other evidence shows that SF-1 regulates many genes involved in development and steroidogenic function (reviewed in Schimmer and White, 2010). SF-1 is generally considered as an activator of gene expression, but it can act as a negative regulator of the type 4 adenylyl cyclase and of CYP11B2 (Rui et al., 2008; Ye et al., 2009). SF-1 also regulates genes involved in sex determination and development of reproductive tissues including DAX1, AMH, SOX9, SRY (Kawabe et al., 1999; De Santa Barbara et al., 1998; De Santa Barbara et al.,2001; Sekido et al., 2008). Thus, SF-1 plays a central role in development and function of the steroidogenic and reproductive systems.
Some SF-1-interacting proteins (positive and negative cofactors) are expressed in a tissue-specific manner whereas others are more widely expressed. Further studies are necessary to better understand how these cofactors could contribute to control cell- and time-specific expression of SF-1-dependent genes. Interactions between SF-1 and DAX-1 represent a particular interest (Ikeda et al., 1996). DAX1, an X-linked gene that encodes a repressor of steroidogenic gene expression, modulates the activity of SF-1 (Lalli et al., 1998). Mutations in DAX-1 cause X-linked adrenal hypoplasia congenita and hypogonadotrophic hypogonadism, phenotypes similar to those seen with NR5A1 mutations (reviewed in Lalli, 2003 and Lalli, 2014).
Putative phospholipid ligands, post-translational modifications (phosphorylation, sumoylation, acetylation), epigenetic gene expression regulation and gene dosage (see below) can influence SF-1 transcriptional activity, subnuclear localization and/or DNA-binding activity (reviewed in Hoivik et al., 2010; Lalli, 2010; Schimmer and White, 2010).
By different genomic approaches, multiple levels of regulation exerted by SF-1 dosage on transcriptome, and more recently on its cistrome have been explored (Doghman et al., 2007; Doghman et al., 2013). These recent studies have shown that SF-1 regulates distinct categories of genes in adrenocortical cancer cells according to its dosage. Moreover, the binding of SF-1 to chromatin sites in condition of different SF-1 dosage correlates with differential regulation of gene expression (Doghman et al., 2013). Transcriptional profiling revealed that SF-1 dosage-dependent genes are involved in lipid and steroid metabolism, but also in apoptosis, cell cycle regulation, cell adhesion and transcriptional regulation (reviewed in Lalli et al., 2013). Other recent studies show that SF-1 knockdown affects the expression of a large number of transcripts that are not only involved in steroid synthesis (Schimmer et al., 2011). A recent study suggested that SF-1 may be involved in glucose metabolism by regulating genes of the glycolytic pathways (Baba et al., 2014) even if this was not observed in other studies (Schimmer et al., 2011; Doghman et al., 2013).
From Knock-out mice models to human mutations phenotype: Evidence of the key role of SF-1 in differentiation and development.
Studies of both complete and tissue-specific knockout mice have demonstrated that SF-1 is a key factor for the development of the adrenal glands, gonads, ventromedial hypothalamus and in pituitary gonadotropes functions (Luo et al., 1994; Sadovsky et al., 1995; Shinoda et al., 1995; Ikeda et al., 1995; Zhao et al., 2001). To characterize the role of SF-1 in different tissues and to distinguish between the direct and secondary effects of SF-1 deficiency, Keith Parker's laboratory developed mice models that are specifically deleted for Sf-1 in gonadotrope cells, gonads and VMH by using the Cre/lox approach (Jeyasuria et al., 2004; Pelusi et al., 2008; Zhao et al., 2008).
Role in adrenal and gonads
Sf-1 null mice lack adrenal glands and gonads and die from adrenal insufficiency within the first week after birth. Mice lacking Sf-1 show early adrenal and gonadal development that regresses by apoptosis between E11.5 and E12.5 (Luo et al., 1994; Sadovsky et al., 1995) indicating that Sf-1 is essential for early development and maintenance of adrenal and gonadal primordia.
SF-1 knockout mice exhibited male-to-female sex reversal of their internal and external genitalia. Since their gonads regressed before male sexual differentiation normally occurs, the internal and external urogenital tracts of SF-1 KO mice are female irrespective of genetic sex. Absence of testes in homozygous mutant male mice precludes MIS (Müllerian inhibiting substance) and androgen production, which accounts for the observed phenotypes (Luo et al., 1994; Sadovsky et al., 1995).
Heterozygous Sf-1 null mice have decreased adrenal volume associated with impaired corticosterone production in response to stress and present smaller testes (Bland et al., 2000). These mice also present a defect in compensatory growth in the remaining adrenal following unilateral adrenalectomy, indicating that SF-1 is required for cell proliferation in steroidogenic tissue (Beuschlein et al., 2002). Differences in adrenal development between heterozygous animals and their wild-type littermates were more evident during embryonic development than postnatally due to a partial compensation of adrenal function after birth (Bland et al., 2004). Thus, a difference between the capacity of the adrenal gland and gonad to compensate for partial loss of SF-1 function might be one of the mechanisms explaining why the gonadal phenotype is more marked than the adrenal phenotype in humans with heterozygous NR5A1 mutations (see Implications in pathology).
Male gonad-specific Sf-1 KO mice display hypoplastic testes observed starting from early developmental stages associated with an impaired spermatogenesis which makes the animals sterile. Moreover, in this model, the testes do not descend (cryptorchidism), demonstrating an in vivo important role of SF-1 in hormonal production for virilization and testes descent (Jeyasuria et al., 2004). Sf-1 KO ovaries were indistinguishable from wild-type during embryogenesis and at birth, but adult females were sterile. In the ovaries, the total number of ovarian follicles is decreased and corpora lutea are lacking, indicating an important role for SF-1 in ovulation (Jeyasuria et al., 2004). SF-1 is then essential for normal gonadal function in both male and female mice.
Role in anterior pituitary, VMH and spleen
The consequences of SF-1 KO at the level of pituitary and hypothalamus have important impacts on their target organs. Indeed, the pituitaries of SF1 knockout mice have markedly decreased expression of both pituitary gonadotropins [luteinizing hormone (LH) and follicle-stimulating hormone (FSH)] and have impaired expression of many target genes that regulate gonadal steroidogenesis (Ingraham et al., 1994; Shinoda et al., 1995). However, GnRH treatment of SF-1 knockout mice induced pituitary expression of LH and FSH, indicating that gonadotropes can express putative SF-1 target genes in the absence of SF-1 (Ikeda et al., 1995).
The pituitary-specific Sf-1 KO mice have markedly decreased levels of LH and FSH and exhibit hypoplastic gonads, impaired secondary sexual development and are sterile. Administration of gonadotropins partially rescues the gonadal phenotype. All these studies establish a primary role for SF-1 in gonadotrope function in the pituitary in mice (Zhao et al., 2001).
In the brain of SF-1 KO mice, the region of the ventromedial hypothalamus is disorganized and does not show its characteristic structures. The VMH is a hypothalamic region linked to feeding and appetite regulation and female reproductive behavior (Shinoda et al., 1995; Ikeda et al., 1995; Zhao et al., 2001). SF-1 is the only gene that is specifically and exclusively expressed in the VMH. It is noteworthy that SF-1 KO mice that are maintained alive by adrenal transplantation exhibit late onset obesity suggesting a potential role of SF-1 in regulation of food intake (Majdic et al., 2002).
The nestin promoter, which is active in the CNS, was used to create a brain-specific Sf-1 KO micenCre; F/- model equivalent of a VMH-specific knockout (Zhao et al., 2008). The organization of VMH neurons is dramatically changed in this model, and mice also present an increased anxiety-like behavior and a decreased locomotor activity (Zhao et al., 2008). Moreover, Sf-1 KOnCre; F/- female mice have impaired follicle development, fertility and sexual behaviors and normal body weight, delineating an important role for SF-1 expressed in the VMH in female reproductive function, independently of energy balance regulation (Kim et al., 2010). To distinguish between the direct metabolic roles of SF-1 and its developmental side effects, an alternative mouse model named postnatal VMH-specific SF-1 KO was generated in which SF-1 is specifically deleted after completion of VMH development using CamKII-Cre, a postnatally expressing Cre line (Kim et al., 2011). These postnatal VMH-specific Sf-1 KO animals display a diet-induced obesity and revealed that SF-1 is required for normal energy homeostasis by modulating energy expenditure especially in high-fat diet condition (Kim et al., 2010). Although SF-1-expressing neurons do not represent all neurons within the VMH, many studies establish that SF-1 neurons in the VMH are essential for normal energy homeostasis, particularly in regulation of energy expenditure (reviewed in Choi et al., 2013).
It has been shown that disruption of SF-1 also causes developmental abnormalities in spleen tubular structure and impaired clearance by the splenic vascular system (Morohashi et al., 1999). Similar defects have been observed in mice with disruption of the mouse polycomb 33 gene (M33) and suggest an interaction between M33 and SF-1 in splenic development (Katoh-Fukui et al., 2005).
SF-1 involvement in human disease
Genetic evidence for the essential role of SF-1 in endocrine development also comes from studies on human patients. These genetic mutations provide insights into the function of SF-1 and the mechanisms of XY sex reversal, ovarian anomalies and adrenal failure (reviewed in Lin and Achermann, 2008).
More than 70 human SF-1 mutations have been described, with most of them found in a heterozygous state and only a few found in homozygote or compound heterozygote state (see Mutation). In humans, the first description of a heterozygous loss-of-function SF-1 mutation (G35E) was made in a patient with adrenal failure and complete 46,XY sex-reversal, closely matching the phenotype of Sf-1 null mice (Achermann et al., 1999). Afterwards, several other patients have been described presenting variable degrees of gonadal and adrenal dysgenesis caused by SF-1 haploinsufficiency, while only one homozygous SF-1 mutation has been described (R92Q) in a patient with adrenal hypoplasia and 46,XY sex-reversal (Achermann et al., 2002). In several cases, SF-1 haploinsufficiency has been shown to be associated with isolated gonadal dysgenesis or ovarian insufficiency, while only one case has been described of a prepubertal girl with adrenal insufficiency and apparently normal ovaries (Biason-Lauber et al., 2000). It appears that a species difference exists in the sensitivity to SF-1 dosage. In fact, while adrenals and gonads are both affected by Sf-1 haploinsufficiency in mice, in humans the great majority of heterozygote SF-1 mutations are associated with disorders of sex development (Lin et al., 2007), premature ovarian failure (Lourenço et al., 2009) or male infertility (Bashamboo et al., 2010) rather than adrenal development (see Mutation and Implication in pathology).
Recently, novel SF-1 mutations were identified in patients with 46,XY DSD and adrenal insufficiency. In vitro analysis revealed that these SF-1 mutations affect not only steroidogenesis but also transcription of the BDNF gene that is involved in energy balance (Malikova et al., 2014). However, in contrast to mice, consequences on weight were not found in humans with SF-1 mutations and further studies are necessary to confirm the impact of SF-1 on body weight regulation in human.
A recent study describes a clinical phenotype of severe 46,XY-DSD with asplenia, caused by a novel homozygous SF1 mutation (R103Q) suggesting that SF-1 is required for spleen development in humans (Zangen et al., 2014).
SF-1 dosage as a key regulator of adrenocortical growth and of tumorigenesis
The critical role of SF-1 as a developmental regulator became evident by the analysis of the phenotype of Sf-1 KO mice (see above). The role for Sf-1 gene dosage in the development of adrenals is demonstrated by the finding that Sf-1 heterozygous mice have hypoplastic adrenals, with a decreased corticosterone and increased ACTH plasma levels, especially after stress (Bland et al., 2000). Also in the adult mouse Sf-1 dosage is critical for compensatory adrenal growth following unilateral adrenalectomy (Beuschlein et al., 2002).
The function of SF-1 in the regulation of adrenocortical growth has a particular relevance to understand the mechanisms of adrenocortical tumorigenesis. Important input came from pediatric adrenocortical tumors studies. These tumors are particularly frequent in southern Brazil and are associated with the presence of the germline R337H TP53 mutation, NR5A1 copy number gain/gene amplification and SF-1 protein overexpression (Ribeiro et al., 2001; Figueiredo et al., 2005; Pianovski et al., 2006; Letouzé et al., 2012). Subsequent studies involving both a human adrenocortical cell line with inducible SF-1 overexpression and a transgenic mouse model bearing multiple copies of the Sf-1 gene showed that an increased SF-1 dosage activates adrenocortical cell proliferation and induces adrenocortical neoplasia (Karpova et al., 2005; Doghman et al., 2007). Moreover, the transcriptional activation function (AF2 domain) of SF-1 is necessary for its role in adrenocortical cell proliferation. Interestingly, those tumors develop in the subcapsular region of the Sf-1 transgenic adrenal glands and express the gonadal markers Gata4 and AMH, derived most probably from undifferentiated adrenogonadal precursors (Looyenga and Hammer, 2006). Transcriptome analysis revealed that SF-1 regulates new and distinct categories of gene involved in multiple functions according to its dosage (Doghman et al., 2013) (see above). Altogether, it appears that SF-1 dosage plays an important role during adrenal development and tumorigenesis.
Role of SF-1 in embryonic stem (ES) cells differentiation
The role of SF-1 in stem cells differentiation into steroid-producing cells was first investigated in 1997 by Crawford and colleagues (Crawford et al., 1997). They reported that the forced expression of SF-1 directed mouse ES cells into the steroidogenic cell lineage, although the steroidogenic capacity of these cells was very limited. Upon SF-1 transfection, human mesenchymal stem cells (MSC) were shown to be successfully converted into steroidogenic cell lineage appearing to be glucocorticoid- rather than testosterone-producing cells (Yawaza et al., 2006). Moreover, Gondo et al., reported that steroid hormone production was observed for more than 112 d when bone marrow-derived MSC were infected with SF-1 by an adenoviral vector (Gondo et al., 2008). Interestingly introduction of LRH1 (Liver-specific receptor, NR5A2), another member of the NR5A family, resulted in differentiation of human MSCs into steroidogenic cells (Yawaza et al., 2009). In 2011, Yazawa et al., reported a method for differentiating mouse ES cells into steroid-producing cells through tetracycline-controlled transcriptional activation of SF-1 (Yazawa et al., 2011).
It has been demonstrated that human ES/iPS (induced Pluripotent Stem) cells can be differentiated into steroid-producing cells by first inducing them to differentiate into the mesodermal lineage and then introducing SF-1 (Sonoyama et al., 2012). The steroidogenic cells obtained expressed mRNAs encoding adrenocortical or gonad-specific steroidogenic enzymes and produced a wide variety of steroid (Sonoyama et al., 2012). All these findings indicate that SF-1 could work as a differentiating factor for the steroidogenic differentiation of multipotent stem cells and open new perspectives for future regenerative therapy.

Mutations

Note Studies carried out on human patients provided genetic evidence for the pivotal role of SF-1 in endocrine development. Several SF-1 mutations have been described in humans and are associated with a wide variety of human reproductive phenotypes, like 46,XY disorders of sex development (DSD), hypospadias, anorchia, male infertility or primary ovarian insufficiency in women and adrenal failure (reviewed in Lin and Achermann, 2008; Ferraz-de-Souza et al., 2011; Human Gene Mutation Database). Several of these genetic alterations are represented by heterozygous nonsense or frameshift mutations which alter RNA stability through nonsense-mediated decay or produce a truncated non-functional protein (reviewed in Lin and Achermann, 2008). Other genetic alterations are present as nucleotide polymorphisms or deletions.
Several novel heterozygous missense mutations identified provide interesting insights into SF-1 structure-function correlation. As described below, most of those missense mutations lie within the primary or accessory DBD affecting highly-conserved aminoacid residues (reviewed in Lin and Achermann, 2008). These genetic alterations interfered with DNA binding and inhibited transcriptional activation in transient gene expression assays.
The earliest studies on NR5A1 mutations were based on single case reports (Achermann et al., 1999; Achermann et al., 2002). They focused on the rare group of 46,XY females exhibiting primary adrenal failure, severe gonadal dysgenesis and persistence of Mülleran structures (a phenotype resembling Sf-1 null knockout mice). The first patient showed a heterozygous de novo G35E mutation which disrupts the P-box primary DNA-binding motif within the first zinc finger of SF-1 DBD (see Protein description), thus resulting in diminished target gene binding and transactivation (Achermann et al., 1999; Ito et al., 2000a; Tremblay et al., 2003). The second patient exhibited a homozygous R92Q mutation within the A-box (see Protein description), resulting in a variable and partial loss of SF-1 activity (Achermann et al., 2002).
Other reported mutations were shown to impair transcriptional activity through abnormal DNA binding (V15M, M78I, G19S), perturbed sub-nuclear localization (V15M, M78I, as well as another mutation in the DBD, C33S, Köhler et al., 2008) or by disrupting the putative ligand-binding pocket (L437Q) (Lin et al., 2007). Another mutation affecting the proximal part of the SF-1 LBD is R255L, a de novo heterozygous change identified in a girl showing primary adrenal insufficiency at 14 months of age (Biason-Lauber and Schoenle, 2000). The mutant SF-1 protein was shown to be transcriptionally inactive, but without a dominant negative effect.
Further, in-frame deletions and frameshift and missense mutations have been detected in four families with histories of both 46,XY DSD and 46,XX primary ovarian insufficiency and in 2 of 25 patients with sporadic ovarian insufficiency (Lourenço et al., 2009). Functional studies showed that those mutations substantially impaired SF-1 transactivation activity. One of the mutation identified by Lourenço et al. in the LBD is D293N. The mutated protein partly activated both CYP11A1 and CYP19A1 promoters (Lourenço et al., 2009). Homozigosity for D293N caused either 46, XY complete gonadal dysgenesis or 46, XY DSD, suggesting a pivotal role of this domain in modulating male sex differentiation.
NR5A1 mutations can affect also the hinge region of the protein (see Protein structure). The first mutation discovered in the hinge region was G146A (WuQiang et al., 2003). The mutated protein shows slightly diminished transactivation activity on the CYP11A promoter and the CYP19 promoter II. However, the mutation does not alter protein expression or stability and does not display dominant negative effect.
Recent studies in patients with novel NR5A1 mutations have shown no clear genotype-structure-function-phenotype correlation (Camats et al., 2012). Thus, further investigation is necessary to better understand the broad range of clinical manifestations produced by SF-1 mutations.

Implicated in

Note
  
Entity SF-1 expression in prostate cancer
Note Recently, it has been reported that SF1 is expressed in prostate cancer cells but not in normal prostate. SF-1 expression stimulates local and autonomous steroid production necessary to induce proliferation and survival that contribute to aggressive prostate cancer (Lewis et al., 2014).
  
  
Entity SF-1 overexpression and adrenal tumorigenesis
Note Important insights into the key role of SF-1 dosage came from pediatric adrenocortical tumors analysis. Using comparative genomic hybridization (CGH) and SNP array profiling, a high frequency of chromosomal aberrations and amplification of 9q33-q34 region, harboring the SF-1 gene, emerged as the most consistent finding in a majority childhood adrenocortical tumors (Figueiredo et al., 1999; Figueiredo et al., 2005; Pianovski et al., 2006; Letouzé et al., 2012). SF-1 overexpression has been shown to increase proliferation of human adrenocortical cells, and to induce adrenocortical tumors in Sf-1 transgenic mice (Doghman et al., 2007) (see above). Further studies have shown that the levels of SF-1 expression represent a stage-independent prognostic indicator in patients with adrenocortical cancer (Sbiera et al., 2010). SF-1 dosage is then considered as a critical factor in adrenocortical tumorigenesis (reviewed in Lalli, 2010).
  
  
Entity SF-1 expression in endometriosis
Note SF-1 is expressed in endometriotic cells whereas it is not usually detected in normal endometrium and can exert a role in the pathogenesis of endometriosis (Xue et al., 2007; reviewed in Bulun et al., 2009). SF-1 expression leads to an aberrant activation of StAR and CYP19 genes expression and to an increase of the endogenous synthesis of estrogen within endometriotic tissue, a key causative factor in the disease. This aberrant expression seems to be explained by modifications in the regulation of SF-1 expression by DNA methylation of CpG islands in the promoter, intron 1, and exon 2/intron 3 regions (Xue et al., 2014).
  
  
Entity 46 XY, development of sex disorders (DSD)
Note Heterozygous NR5A1 mutations emerge as a relatively frequent finding in patient with 46,XY DSD from typical to severe phenotype, but without adrenal insufficiency. The patients present a phenotype of ambiguous or female external genitalia at birth and small inguinal testes. Müllerian structures may be present or absent, and Wolffian structures are often seen. There is a significant biochemical evidence of partial gonadal dysgenesis with impaired androgen synthesis, that contributes to the phenotype, as shown by low levels of testosterone, inhibin β and AMH and an elevation of FSH (reviewed in Lin and Achermann, 2008).
NR5A1 mutations have also been detected in 46, XY patients with severe hypospadia and small inguinal testes due to partial dysgenesis and /or a reduced androgen synthesis (Lin et al., 2007). SF-1 was also considered as a candidate gene for bilateral anorchidia based on the study of a cohort of 24 boys where one boy carried a heterozygous NR5A1 mutation. He presented one absent testis, one very small testis with undectable AMH in early infancy, and later a testis atrophy in childhood (Philibert et al., 2007). However the patient's twin brother who harbored the same mutation underwent normal puberty suggesting that, despite incomplete penetrance of NR5A1 mutations, SF-1 could participate in maintaining the testis.
A study identified heterozygous NR5A1 mutations, localized in the hinge region and proximal LBD of the protein, associated with spermatogenic failure (from moderate oligospermia to azoospermia) in healthy men, widening the range of gonadal phenotypes associated with NR5A1 mutations (Bashamboo et al., 2010).
  
  
Entity Adrenal insufficiency
Note Given the central role of SF-1 in adrenal development and steroidogenesis, several studies have looked for NR5A1 mutations in children and adults with primary adrenal insufficiency. Only few cases have been described of NR5A1 mutations that also produce adrenal insufficiency in addition to gonadal defects (Achermann et al., 1999; Achermann et al., 2002; Malikova et al., 2014). A single case of a prepubertal girl where adrenal insufficiency was associated with apparent normal ovarian development has been reported (Biason-Lauber and Schoenle, 2000).
In another study, no NR5A1 mutations were identified in a small cohort of girls diagnosed with adrenal hypoplasia (Lin et al., 2006). Similarly, no significant NR5A1 changes were found in boys affected by adrenal hypoplasia without DAX1 mutations (Lin et al., 2006). Thus, NR5A1 mutations seem not to be a common cause of primary adrenal failure in boys without reproductive dysfunction or 46,XY DSD.
  
  
Entity Primary ovarian insufficiency (POI)
Note NR5A1 mutations have been identified in familial and sporadic forms of 46,XX primary ovarian insufficiency (Lourenço et al., 2009). These 46XX patients presented either primary or secondary amenorrhea at variable ages. Primary gonadal failure was associated with elevated LH and FSH and low estrogen levels. These NR5A1 mutations, detected in subjects with anomalies of ovarian development and function, are associated with an impairment of transactivation on the CYP11A1 and CYP19A1 promoters. Detection of NR5A1 mutations in 46, XX women with ovarian failure shows that SF-1 is an important factor in ovarian development and function in humans.
  

Bibliography

Gonadal determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic factor-1, in a dose-dependent manner.
Achermann JC, Ozisik G, Ito M, Orun UA, Harmanci K, Gurakan B, Jameson JL.
J Clin Endocrinol Metab. 2002 Apr;87(4):1829-33.
PMID 11932325
 
Glycolytic genes are targets of the nuclear receptor Ad4BP/SF-1.
Baba T, Otake H, Sato T, Miyabayashi K, Shishido Y, Wang CY, Shima Y, Kimura H, Yagi M, Ishihara Y, Hino S, Ogawa H, Nakao M, Yamazaki T, Kang D, Ohkawa Y, Suyama M, Chung BC, Morohashi K.
Nat Commun. 2014 Apr 14;5:3634. doi: 10.1038/ncomms4634.
PMID 24727981
 
Mutually exclusive interactions of two nuclear orphan receptors determine activity of a cyclic adenosine 3',5'-monophosphate-responsive sequence in the bovine CYP17 gene.
Bakke M, Lund J.
Mol Endocrinol. 1995 Mar;9(3):327-39.
PMID 7776979
 
Human male infertility associated with mutations in NR5A1 encoding steroidogenic factor 1.
Bashamboo A, Ferraz-de-Souza B, Lourenco D, Lin L, Sebire NJ, Montjean D, Bignon-Topalovic J, Mandelbaum J, Siffroi JP, Christin-Maitre S, Radhakrishna U, Rouba H, Ravel C, Seeler J, Achermann JC, McElreavey K.
Am J Hum Genet. 2010 Oct 8;87(4):505-12. doi: 10.1016/j.ajhg.2010.09.009.
PMID 20887963
 
Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1.
Bassett MH, Zhang Y, Clyne C, White PC, Rainey WE.
J Mol Endocrinol. 2002 Apr;28(2):125-35.
PMID 11932209
 
Steroidogenic factor-1 is essential for compensatory adrenal growth following unilateral adrenalectomy.
Beuschlein F, Mutch C, Bavers DL, Ulrich-Lai YM, Engeland WC, Keegan C, Hammer GD.
Endocrinology. 2002 Aug;143(8):3122-35.
PMID 12130578
 
Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency.
Biason-Lauber A, Schoenle EJ.
Am J Hum Genet. 2000 Dec;67(6):1563-8. Epub 2000 Oct 18.
PMID 11038323
 
The LIM homeobox gene Lhx9 is essential for mouse gonad formation.
Birk OS, Casiano DE, Wassif CA, Cogliati T, Zhao L, Zhao Y, Grinberg A, Huang S, Kreidberg JA, Parker KL, Porter FD, Westphal H.
Nature. 2000 Feb 24;403(6772):909-13.
PMID 10706291
 
Differential requirement for steroidogenic factor-1 gene dosage in adrenal development versus endocrine function.
Bland ML, Fowkes RC, Ingraham HA.
Mol Endocrinol. 2004 Apr;18(4):941-52. Epub 2004 Jan 15.
PMID 14726490
 
Haploinsufficiency of steroidogenic factor-1 in mice disrupts adrenal development leading to an impaired stress response.
Bland ML, Jamieson CA, Akana SF, Bornstein SR, Eisenhofer G, Dallman MF, Ingraham HA.
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14488-93.
PMID 11121051
 
Steroidogenic factor-1 and endometriosis.
Bulun SE, Utsunomiya H, Lin Z, Yin P, Cheng YH, Pavone ME, Tokunaga H, Trukhacheva E, Attar E, Gurates B, Milad MP, Confino E, Su E, Reierstad S, Xue Q.
Mol Cell Endocrinol. 2009 Mar 5;300(1-2):104-8. doi: 10.1016/j.mce.2008.12.012. Epub 2008 Dec 25. (REVIEW)
PMID 19150483
 
Ten novel mutations in the NR5A1 gene cause disordered sex development in 46,XY and ovarian insufficiency in 46,XX individuals.
Camats N, Pandey AV, Fernandez-Cancio M, Andaluz P, Janner M, Toran N, Moreno F, Bereket A, Akcay T, Garcia-Garcia E, Munoz MT, Gracia R, Nistal M, Castano L, Mullis PE, Carrascosa A, Audi L, Fluck CE.
J Clin Endocrinol Metab. 2012 Jul;97(7):E1294-306. doi: 10.1210/jc.2011-3169. Epub 2012 May 1.
PMID 22549935
 
Role of steroidogenic-factor 1 in basal and 3',5'-cyclic adenosine monophosphate-mediated regulation of cytochrome P450 side-chain cleavage enzyme in the mouse.
Chau YM, Crawford PA, Woodson KG, Polish JA, Olson LM, Sadovsky Y.
Biol Reprod. 1997 Oct;57(4):765-71.
PMID 9314578
 
SF-1 (nuclear receptor 5A1) activity is activated by cyclic AMP via p300-mediated recruitment to active foci, acetylation, and increased DNA binding.
Chen WY, Juan LJ, Chung BC.
Mol Cell Biol. 2005 Dec;25(23):10442-53.
PMID 16287857
 
SUMO modification of repression domains modulates function of nuclear receptor 5A1 (steroidogenic factor-1).
Chen WY, Lee WC, Hsu NC, Huang F, Chung BC.
J Biol Chem. 2004 Sep 10;279(37):38730-5. Epub 2004 Jun 10.
PMID 15192092
 
Histone deacetylase inhibitors reduce steroidogenesis through SCF-mediated ubiquitination and degradation of steroidogenic factor 1 (NR5A1).
Chen WY, Weng JH, Huang CC, Chung BC.
Mol Cell Biol. 2007 Oct;27(20):7284-90. Epub 2007 Aug 20.
PMID 17709382
 
Revisiting the Ventral Medial Nucleus of the Hypothalamus: The Roles of SF-1 Neurons in Energy Homeostasis.
Choi YH, Fujikawa T, Lee J, Reuter A, Kim KW.
Front Neurosci. 2013 May 7;7:71. doi: 10.3389/fnins.2013.00071. eCollection 2013.
PMID 23675313
 
Nuclear receptor steroidogenic factor 1 directs embryonic stem cells toward the steroidogenic lineage.
Crawford PA, Sadovsky Y, Milbrandt J.
Mol Cell Biol. 1997 Jul;17(7):3997-4006.
PMID 9199334
 
Disrupted gonadogenesis and male-to-female sex reversal in Pod1 knockout mice.
Cui S, Ross A, Stallings N, Parker KL, Capel B, Quaggin SE.
Development. 2004 Aug;131(16):4095-105.
PMID 15289436
 
Direct interaction of SRY-related protein SOX9 and steroidogenic factor 1 regulates transcription of the human anti-Müllerian hormone gene.
De Santa Barbara P, Bonneaud N, Boizet B, Desclozeaux M, Moniot B, Sudbeck P, Scherer G, Poulat F, Berta P.
Mol Cell Biol. 1998 Nov;18(11):6653-65.
PMID 9774680
 
Phosphorylation and intramolecular stabilization of the ligand binding domain in the nuclear receptor steroidogenic factor 1.
Desclozeaux M, Krylova IN, Horn F, Fletterick RJ, Ingraham HA.
Mol Cell Biol. 2002 Oct;22(20):7193-203.
PMID 12242296
 
Integrative analysis of SF-1 transcription factor dosage impact on genome-wide binding and gene expression regulation.
Doghman M, Figueiredo BC, Volante M, Papotti M, Lalli E.
Nucleic Acids Res. 2013 Oct;41(19):8896-907. doi: 10.1093/nar/gkt658. Epub 2013 Aug 1.
PMID 23907384
 
Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer.
Doghman M, Karpova T, Rodrigues GA, Arhatte M, De Moura J, Cavalli LR, Virolle V, Barbry P, Zambetti GP, Figueiredo BC, Heckert LL, Lalli E.
Mol Endocrinol. 2007 Dec;21(12):2968-87. Epub 2007 Aug 30.
PMID 17761949
 
The steroid and thyroid hormone receptor superfamily.
Evans RM.
Science. 1988 May 13;240(4854):889-95. (REVIEW)
PMID 3283939
 
Protein kinase A potentiates adrenal 4 binding protein/steroidogenic factor 1 transactivation by reintegrating the subcellular dynamic interactions of the nuclear receptor with its cofactors, general control nonderepressed-5/transformation/transcription domain-associated protein, and suppressor, dosage-sensitive sex reversal-1: a laser confocal imaging study in living KGN cells.
Fan W, Yanase T, Wu Y, Kawate H, Saitoh M, Oba K, Nomura M, Okabe T, Goto K, Yanagisawa J, Kato S, Takayanagi R, Nawata H.
Mol Endocrinol. 2004 Jan;18(1):127-41. Epub 2003 Oct 10.
PMID 14555713
 
Steroidogenic factor-1 (SF-1, NR5A1) and human disease.
Ferraz-de-Souza B, Lin L, Achermann JC.
Mol Cell Endocrinol. 2011 Apr 10;336(1-2):198-205. doi: 10.1016/j.mce.2010.11.006. Epub 2010 Nov 13. (REVIEW)
PMID 21078366
 
Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors.
Figueiredo BC, Cavalli LR, Pianovski MA, Lalli E, Sandrini R, Ribeiro RC, Zambetti G, DeLacerda L, Rodrigues GA, Haddad BR.
J Clin Endocrinol Metab. 2005 Feb;90(2):615-9. Epub 2004 Nov 16.
PMID 15546904
 
Adipose tissue-derived and bone marrow-derived mesenchymal cells develop into different lineage of steroidogenic cells by forced expression of steroidogenic factor 1.
Gondo S, Okabe T, Tanaka T, Morinaga H, Nomura M, Takayanagi R, Nawata H, Yanase T.
Endocrinology. 2008 Sep;149(9):4717-25. doi: 10.1210/en.2007-1808. Epub 2008 Jun 19.
PMID 18566117
 
Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: integration of hormone signaling in reproduction and stress.
Hammer GD, Krylova I, Zhang Y, Darimont BD, Simpson K, Weigel NL, Ingraham HA.
Mol Cell. 1999 Apr;3(4):521-6.
PMID 10230405
 
Expression of steroidogenic factor 1 and Wilms' tumour 1 during early human gonadal development and sex determination.
Hanley NA, Ball SG, Clement-Jones M, Hagan DM, Strachan T, Lindsay S, Robson S, Ostrer H, Parker KL, Wilson DI.
Mech Dev. 1999 Sep;87(1-2):175-80.
PMID 10495282
 
Expression profiles of SF-1, DAX1, and CYP17 in the human fetal adrenal gland: potential interactions in gene regulation.
Hanley NA, Rainey WE, Wilson DI, Ball SG, Parker KL.
Mol Endocrinol. 2001 Jan;15(1):57-68.
PMID 11145739
 
Identical origin of adrenal cortex and gonad revealed by expression profiles of Ad4BP/SF-1.
Hatano O, Takakusu A, Nomura M, Morohashi K.
Genes Cells. 1996 Jul;1(7):663-71.
PMID 9078392
 
Molecular aspects of steroidogenic factor 1 (SF-1).
Hoivik EA, Lewis AE, Aumo L, Bakke M.
Mol Cell Endocrinol. 2010 Feb 5;315(1-2):27-39. doi: 10.1016/j.mce.2009.07.003. Epub 2009 Jul 16. (REVIEW)
PMID 19616058
 
Ad4BP regulating steroidogenic P-450 gene is a member of steroid hormone receptor superfamily.
Honda S, Morohashi K, Nomura M, Takeya H, Kitajima M, Omura T.
J Biol Chem. 1993 Apr 5;268(10):7494-502.
PMID 8463279
 
Functions of the upstream and proximal steroidogenic factor 1 (SF-1)-binding sites in the CYP11A1 promoter in basal transcription and hormonal response.
Hu MC, Hsu NC, Pai CI, Wang CK, Chung Bc.
Mol Endocrinol. 2001 May;15(5):812-8.
PMID 11328860
 
Characterization of the mouse FTZ-F1 gene, which encodes a key regulator of steroid hydroxylase gene expression.
Ikeda Y, Lala DS, Luo X, Kim E, Moisan MP, Parker KL.
Mol Endocrinol. 1993 Jul;7(7):852-60.
PMID 8413309
 
The nuclear receptor steroidogenic factor 1 is essential for the formation of the ventromedial hypothalamic nucleus.
Ikeda Y, Luo X, Abbud R, Nilson JH, Parker KL.
Mol Endocrinol. 1995 Apr;9(4):478-86.
PMID 7659091
 
Developmental expression of mouse steroidogenic factor-1, an essential regulator of the steroid hydroxylases.
Ikeda Y, Shen WH, Ingraham HA, Parker KL.
Mol Endocrinol. 1994 May;8(5):654-62.
PMID 8058073
 
Steroidogenic factor 1 and Dax-1 colocalize in multiple cell lineages: potential links in endocrine development.
Ikeda Y, Swain A, Weber TJ, Hentges KE, Zanaria E, Lalli E, Tamai KT, Sassone-Corsi P, Lovell-Badge R, Camerino G, Parker KL.
Mol Endocrinol. 1996 Oct;10(10):1261-72.
PMID 9121493
 
Comparative localization of Dax-1 and Ad4BP/SF-1 during development of the hypothalamic-pituitary-gonadal axis suggests their closely related and distinct functions.
Ikeda Y, Takeda Y, Shikayama T, Mukai T, Hisano S, Morohashi KI.
Dev Dyn. 2001 Apr;220(4):363-76.
PMID 11307169
 
The nuclear receptor steroidogenic factor 1 acts at multiple levels of the reproductive axis.
Ingraham HA, Lala DS, Ikeda Y, Luo X, Shen WH, Nachtigal MW, Abbud R, Nilson JH, Parker KL.
Genes Dev. 1994 Oct 1;8(19):2302-12.
PMID 7958897
 
A naturally occurring steroidogenic factor-1 mutation exhibits differential binding and activation of target genes.
Ito M, Achermann JC, Jameson JL.
J Biol Chem. 2000a Oct 13;275(41):31708-14.
PMID 10913126
 
Synergistic activation of the inhibin alpha-promoter by steroidogenic factor-1 and cyclic adenosine 3',5'-monophosphate.
Ito M, Park Y, Weck J, Mayo KE, Jameson JL.
Mol Endocrinol. 2000b Jan;14(1):66-81.
PMID 10628748
 
Cell-specific knockout of steroidogenic factor 1 reveals its essential roles in gonadal function.
Jeyasuria P, Ikeda Y, Jamin SP, Zhao L, De Rooij DG, Themmen AP, Behringer RR, Parker KL.
Mol Endocrinol. 2004 Jul;18(7):1610-9. Epub 2004 Apr 29.
PMID 15118069
 
Transgenic rescue of SF-1-null mice.
Karpova T, Maran RR, Presley J, Scherrer SP, Tejada L, Heckert LL.
Ann N Y Acad Sci. 2005 Dec;1061:55-64.
PMID 16467257
 
Mouse Polycomb M33 is required for splenic vascular and adrenal gland formation through regulating Ad4BP/SF1 expression.
Katoh-Fukui Y, Owaki A, Toyama Y, Kusaka M, Shinohara Y, Maekawa M, Toshimori K, Morohashi K.
Blood. 2005 Sep 1;106(5):1612-20. Epub 2005 May 17.
PMID 15899914
 
Dax-1 as one of the target genes of Ad4BP/SF-1.
Kawabe K, Shikayama T, Tsuboi H, Oka S, Oba K, Yanase T, Nawata H, Morohashi K.
Mol Endocrinol. 1999 Aug;13(8):1267-84.
PMID 10446902
 
CNS-specific ablation of steroidogenic factor 1 results in impaired female reproductive function.
Kim KW, Li S, Zhao H, Peng B, Tobet SA, Elmquist JK, Parker KL, Zhao L.
Mol Endocrinol. 2010 Jun;24(6):1240-50. doi: 10.1210/me.2009-0206. Epub 2010 Mar 25.
PMID 20339005
 
SF-1 in the ventral medial hypothalamic nucleus: a key regulator of homeostasis.
Kim KW, Sohn JW, Kohno D, Xu Y, Williams K, Elmquist JK.
Mol Cell Endocrinol. 2011 Apr 10;336(1-2):219-23. doi: 10.1016/j.mce.2010.11.019. Epub 2010 Nov 24. (REVIEW)
PMID 21111025
 
Five novel mutations in steroidogenic factor 1 (SF1, NR5A1) in 46,XY patients with severe underandrogenization but without adrenal insufficiency.
Kohler B, Lin L, Ferraz-de-Souza B, Wieacker P, Heidemann P, Schroder V, Biebermann H, Schnabel D, Grüters A, Achermann JC.
Hum Mutat. 2008 Jan;29(1):59-64.
PMID 17694559
 
Small ubiquitin-like modifier 1 (SUMO-1) modification of the synergy control motif of Ad4 binding protein/steroidogenic factor 1 (Ad4BP/SF-1) regulates synergistic transcription between Ad4BP/SF-1 and Sox9.
Komatsu T, Mizusaki H, Mukai T, Ogawa H, Baba D, Shirakawa M, Hatakeyama S, Nakayama KI, Yamamoto H, Kikuchi A, Morohashi K.
Mol Endocrinol. 2004 Oct;18(10):2451-62. Epub 2004 Jun 10.
PMID 15192080
 
Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1.
Krylova IN, Sablin EP, Moore J, Xu RX, Waitt GM, MacKay JA, Juzumiene D, Bynum JM, Madauss K, Montana V, Lebedeva L, Suzawa M, Williams JD, Williams SP, Guy RK, Thornton JW, Fletterick RJ, Willson TM, Ingraham HA.
Cell. 2005 Feb 11;120(3):343-55.
PMID 15707893
 
Steroidogenic Factor 1 (NR5A1) resides in centrosomes and maintains genomic stability by controlling centrosome homeostasis.
Lai PY, Wang CY, Chen WY, Kao YH, Tsai HM, Tachibana T, Chang WC, Chung BC.
Cell Death Differ. 2011 Dec;18(12):1836-44. doi: 10.1038/cdd.2011.54. Epub 2011 May 13.
PMID 21566663
 
Steroidogenic factor I, a key regulator of steroidogenic enzyme expression, is the mouse homolog of fushi tarazu-factor I.
Lala DS, Rice DA, Parker KL.
Mol Endocrinol. 1992 Aug;6(8):1249-58.
PMID 1406703
 
Beyond steroidogenesis: novel target genes for SF-1 discovered by genomics.
Lalli E, Doghman M, Latre de Late P, El Wakil A, Mus-Veteau I.
Mol Cell Endocrinol. 2013 May 22;371(1-2):154-9. doi: 10.1016/j.mce.2012.11.005. Epub 2012 Nov 17. (REVIEW)
PMID 23168267
 
DAX-1 blocks steroid production at multiple levels.
Lalli E, Melner MH, Stocco DM, Sassone-Corsi P.
Endocrinology. 1998 Oct;139(10):4237-43.
PMID 9751505
 
DAX-1, an unusual orphan receptor at the crossroads of steroidogenic function and sexual differentiation.
Lalli E, Sassone-Corsi P.
Mol Endocrinol. 2003 Aug;17(8):1445-53. Epub 2003 May 29. (REVIEW)
PMID 12775766
 
Role of Orphan Nuclear receptor DAX-1/NR0B1 in development, physiology and disease
Lalli E.
Advances in Biology. 2014 http://dx.doi.org/10.1155/2014/582749
 
The DEAD-box protein DP103 (Ddx20 or Gemin-3) represses orphan nuclear receptor activity via SUMO modification.
Lee MB, Lebedeva LA, Suzawa M, Wadekar SA, Desclozeaux M, Ingraham HA.
Mol Cell Biol. 2005 Mar;25(5):1879-90.
PMID 15713642
 
Synergistic activation of the human type II 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase promoter by the transcription factor steroidogenic factor-1/adrenal 4-binding protein and phorbol ester.
Leers-Sucheta S, Morohashi K, Mason JI, Melner MH.
J Biol Chem. 1997 Mar 21;272(12):7960-7.
PMID 9065466
 
SNP array profiling of childhood adrenocortical tumors reveals distinct pathways of tumorigenesis and highlights candidate driver genes.
Letouze E, Rosati R, Komechen H, Doghman M, Marisa L, Fluck C, de Krijger RR, van Noesel MM, Mas JC, Pianovski MA, Zambetti GP, Figueiredo BC, Lalli E.
J Clin Endocrinol Metab. 2012 Jul;97(7):E1284-93. doi: 10.1210/jc.2012-1184. Epub 2012 Apr 26.
PMID 22539591
 
Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation.
Lewis SR, Hedman CJ, Ziegler T, Ricke WA, Jorgensen JS.
Endocrinology. 2014 Feb;155(2):358-69. doi: 10.1210/en.2013-1583. Epub 2013 Nov 21.
PMID 24265454
 
Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1.
Li Y, Choi M, Cavey G, Daugherty J, Suino K, Kovach A, Bingham NC, Kliewer SA, Xu HE.
Mol Cell. 2005 Feb 18;17(4):491-502.
PMID 15721253
 
Steroidogenic factor-1 (SF-1, Ad4BP, NR5A1) and disorders of testis development.
Lin L, Achermann JC.
Sex Dev. 2008;2(4-5):200-9. doi: 10.1159/000152036. Epub 2008 Nov 5. (REVIEW)
PMID 18987494
 
Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46,XY disorders of sex development with normal adrenal function.
Lin L, Philibert P, Ferraz-de-Souza B, Kelberman D, Homfray T, Albanese A, Molini V, Sebire NJ, Einaudi S, Conway GS, Hughes IA, Jameson JL, Sultan C, Dattani MT, Achermann JC.
J Clin Endocrinol Metab. 2007 Mar;92(3):991-9. Epub 2007 Jan 2.
PMID 17200175
 
Sequence-specific deoxyribonucleic acid (DNA) recognition by steroidogenic factor 1: a helix at the carboxy terminus of the DNA binding domain is necessary for complex stability.
Little TH, Zhang Y, Matulis CK, Weck J, Zhang Z, Ramachandran A, Mayo KE, Radhakrishnan I.
Mol Endocrinol. 2006 Apr;20(4):831-43. Epub 2005 Dec 8.
PMID 16339274
 
Origin and identity of adrenocortical tumors in inhibin knockout mice: implications for cellular plasticity in the adrenal cortex.
Looyenga BD, Hammer GD.
Mol Endocrinol. 2006 Nov;20(11):2848-63. Epub 2006 Jul 27.
PMID 16873442
 
Mutations in NR5A1 associated with ovarian insufficiency.
Lourenco D, Brauner R, Lin L, De Perdigo A, Weryha G, Muresan M, Boudjenah R, Guerra-Junior G, Maciel-Guerra AT, Achermann JC, McElreavey K, Bashamboo A.
N Engl J Med. 2009 Mar 19;360(12):1200-10. doi: 10.1056/NEJMoa0806228. Epub 2009 Feb 25.
PMID 19246354
 
A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation.
Luo X, Ikeda Y, Parker KL.
Cell. 1994 May 20;77(4):481-90.
PMID 8187173
 
Knockout mice lacking steroidogenic factor 1 are a novel genetic model of hypothalamic obesity.
Majdic G, Young M, Gomez-Sanchez E, Anderson P, Szczepaniak LS, Dobbins RL, McGarry JD, Parker KL.
Endocrinology. 2002 Feb;143(2):607-14.
PMID 1179651
 
Human NR5A1/SF-1 mutations show decreased activity on BDNF (brain-derived neurotrophic factor), an important regulator of energy balance: testing impact of novel SF-1 mutations beyond steroidogenesis.
Malikova J, Camats N, Fernandez-Cancio M, Heath K, Gonzalez I, Caimari M, del Campo M, Albisu M, Kolouskova S, Audi L, Fluck CE.
PLoS One. 2014 Aug 14;9(8):e104838. doi: 10.1371/journal.pone.0104838. eCollection 2014.
PMID 25122490
 
Structural and functional abnormalities in the spleen of an mFtz-F1 gene-disrupted mouse.
Morohashi K, Tsuboi-Asai H, Matsushita S, Suda M, Nakashima M, Sasano H, Hataba Y, Li CL, Fukata J, Irie J, Watanabe T, Nagura H, Li E.
Blood. 1999 Mar 1;93(5):1586-94.
PMID 10029587
 
Gonadal and Extragonadal Functions of Ad4BP/SF-1: Developmental Aspects.
Morohashi Ki.
Trends Endocrinol Metab. 1999 Jul;10(5):169-173.
PMID 10370224
 
An E box element is required for the expression of the ad4bp gene, a mammalian homologue of ftz-f1 gene, which is essential for adrenal and gonadal development.
Nomura M, Bartsch S, Nawata H, Omura T, Morohashi K.
J Biol Chem. 1995 Mar 31;270(13):7453-61.
PMID 7706291
 
Structural characterization of human Ad4bp (SF-1) gene.
Oba K, Yanase T, Nomura M, Morohashi K, Takayanagi R, Nawata H.
Biochem Biophys Res Commun. 1996 Sep 4;226(1):261-7.
PMID 8806624
 
Impaired follicle development and infertility in female mice lacking steroidogenic factor 1 in ovarian granulosa cells.
Pelusi C, Ikeda Y, Zubair M, Parker KL.
Biol Reprod. 2008 Dec;79(6):1074-83. doi: 10.1095/biolreprod.108.069435. Epub 2008 Aug 13.
PMID 18703422
 
Mutational analysis of steroidogenic factor 1 (NR5a1) in 24 boys with bilateral anorchia: a French collaborative study.
Philibert P, Zenaty D, Lin L, Soskin S, Audran F, Leger J, Achermann JC, Sultan C.
Hum Reprod. 2007 Dec;22(12):3255-61. Epub 2007 Oct 16.
PMID 17940071
 
SF-1 overexpression in childhood adrenocortical tumours.
Pianovski MA, Cavalli LR, Figueiredo BC, Santos SC, Doghman M, Ribeiro RC, Oliveira AG, Michalkiewicz E, Rodrigues GA, Zambetti G, Haddad BR, Lalli E.
Eur J Cancer. 2006 May;42(8):1040-3. Epub 2006 Mar 29.
PMID 16574405
 
Steroidogenic factor 1 messenger ribonucleic acid expression in steroidogenic and nonsteroidogenic human tissues: Northern blot and in situ hybridization studies.
Ramayya MS, Zhou J, Kino T, Segars JH, Bondy CA, Chrousos GP.
J Clin Endocrinol Metab. 1997 Jun;82(6):1799-806.
PMID 9177385
 
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma.
Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stratakis CA, Sandrini R.
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5.
PMID 11481490
 
A shared promoter element regulates the expression of three steroidogenic enzymes.
Rice DA, Mouw AR, Bogerd AM, Parker KL.
Mol Endocrinol. 1991 Oct;5(10):1552-61.
PMID 1775136
 
Contributions of specificity protein-1 and steroidogenic factor 1 to Adcy4 expression in Y1 mouse adrenal cells.
Rui X, Tsao J, Scheys JO, Hammer GD, Schimmer BP.
Endocrinology. 2008 Jul;149(7):3668-78. doi: 10.1210/en.2008-0203. Epub 2008 Apr 3.
PMID 18388192
 
Mice deficient in the orphan receptor steroidogenic factor 1 lack adrenal glands and gonads but express P450 side-chain-cleavage enzyme in the placenta and have normal embryonic serum levels of corticosteroids.
Sadovsky Y, Crawford PA, Woodson KG, Polish JA, Clements MA, Tourtellotte LM, Simburger K, Milbrandt J.
Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10939-43.
PMID 7479914
 
High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.
Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B, Beuschlein F, Willenberg HS, Hahner S, Saeger W, Bertherat J, Allolio B, Fassnacht M.
J Clin Endocrinol Metab. 2010 Oct;95(10):E161-71. doi: 10.1210/jc.2010-0653. Epub 2010 Jul 21.
PMID 20660055
 
Contributions of steroidogenic factor 1 to the transcription landscape of Y1 mouse adrenocortical tumor cells.
Schimmer BP, Tsao J, Cordova M, Mostafavi S, Morris Q, Scheys JO.
Mol Cell Endocrinol. 2011 Apr 10;336(1-2):85-91. doi: 10.1016/j.mce.2010.11.024. Epub 2010 Nov 25.
PMID 21111771
 
Sex determination involves synergistic action of SRY and SF1 on a specific Sox9 enhancer.
Sekido R, Lovell-Badge R.
Nature. 2008 Jun 12;453(7197):930-4. doi: 10.1038/nature06944. Epub 2008 May 4.
PMID 18454134
 
Identification of an enhancer in the Ad4BP/SF-1 gene specific for fetal Leydig cells.
Shima Y, Miyabayashi K, Baba T, Otake H, Katsura Y, Oka S, Zubair M, Morohashi K.
Endocrinology. 2012 Jan;153(1):417-25. doi: 10.1210/en.2011-1407. Epub 2011 Nov 29.
PMID 22128023
 
Pituitary homeobox 2 regulates adrenal4 binding protein/steroidogenic factor-1 gene transcription in the pituitary gonadotrope through interaction with the intronic enhancer.
Shima Y, Zubair M, Komatsu T, Oka S, Yokoyama C, Tachibana T, Hjalt TA, Drouin J, Morohashi K.
Mol Endocrinol. 2008 Jul;22(7):1633-46. doi: 10.1210/me.2007-0444. Epub 2008 Apr 16.
PMID 18417734
 
Developmental defects of the ventromedial hypothalamic nucleus and pituitary gonadotroph in the Ftz-F1 disrupted mice.
Shinoda K, Lei H, Yoshii H, Nomura M, Nagano M, Shiba H, Sasaki H, Osawa Y, Ninomiya Y, Niwa O, et al.
Dev Dyn. 1995 Sep;204(1):22-9.
PMID 8563022
 
Differentiation of human embryonic stem cells and human induced pluripotent stem cells into steroid-producing cells.
Sonoyama T, Sone M, Honda K, Taura D, Kojima K, Inuzuka M, Kanamoto N, Tamura N, Nakao K.
Endocrinology. 2012 Sep;153(9):4336-45. doi: 10.1210/en.2012-1060. Epub 2012 Jul 9.
PMID 22778223
 
Steroidogenic factor 1-dependent promoter activity of the human steroidogenic acute regulatory protein (StAR) gene.
Sugawara T, Holt JA, Kiriakidou M, Strauss JF 3rd.
Biochemistry. 1996 Jul 16;35(28):9052-9.
PMID 8703908
 
Mouse Dax1 expression is consistent with a role in sex determination as well as in adrenal and hypothalamus function.
Swain A, Zanaria E, Hacker A, Lovell-Badge R, Camerino G.
Nat Genet. 1996 Apr;12(4):404-9.
PMID 8630494
 
The mouse Ftzf1 gene required for gonadal and adrenal development maps to mouse chromosome 2.
Swift S, Ashworth A.
Genomics. 1995 Aug 10;28(3):609-10.
PMID 7490110
 
Homologs of Drosophila Fushi-Tarazu factor 1 map to mouse chromosome 2 and human chromosome 9q33.
Taketo M, Parker KL, Howard TA, Tsukiyama T, Wong M, Niwa O, Morton CC, Miron PM, Seldin MF.
Genomics. 1995 Jan 20;25(2):565-7.
PMID 7789992
 
Hormonal and developmental regulation of DAX-1 expression in Sertoli cells.
Tamai KT, Monaco L, Alastalo TP, Lalli E, Parvinen M, Sassone-Corsi P.
Mol Endocrinol. 1996 Dec;10(12):1561-9.
PMID 8961266
 
Pod-1/Capsulin shows a sex- and stage-dependent expression pattern in the mouse gonad development and represses expression of Ad4BP/SF-1.
Tamura M, Kanno Y, Chuma S, Saito T, Nakatsuji N.
Mech Dev. 2001 Apr;102(1-2):135-44.
PMID 11287187
 
Steroidogenic factor 1/adrenal 4 binding protein transforms human bone marrow mesenchymal cells into steroidogenic cells.
Tanaka T, Gondo S, Okabe T, Ohe K, Shirohzu H, Morinaga H, Nomura M, Tani K, Takayanagi R, Nawata H, Yanase T.
J Mol Endocrinol. 2007 Nov;39(5):343-50.
PMID 17975261
 
A mutated form of steroidogenic factor 1 (SF-1 G35E) that causes sex reversal in humans fails to synergize with transcription factor GATA-4.
Tremblay JJ, Viger RS.
J Biol Chem. 2003 Oct 24;278(43):42637-42. Epub 2003 Aug 6.
PMID 12907682
 
Defining the sequence recognized with BmFTZ-F1, a sequence specific DNA binding factor in the silkworm, Bombyx mori, as revealed by direct sequencing of bound oligonucleotides and gel mobility shift competition analysis.
Ueda H, Hirose S.
Nucleic Acids Res. 1991 Jul 11;19(13):3689-93.
PMID 1852610
 
A sequence-specific DNA-binding protein that activates fushi tarazu segmentation gene expression.
Ueda H, Sonoda S, Brown JL, Scott MP, Wu C.
Genes Dev. 1990 Apr;4(4):624-35.
PMID 2113881
 
Adrenal development is initiated by Cited2 and Wt1 through modulation of Sf-1 dosage.
Val P, Martinez-Barbera JP, Swain A.
Development. 2007 Jun;134(12):2349-58.
PMID 17537799
 
Distinct functions of steroidogenic factor-1 (NR5A1) in the nucleus and the centrosome.
Wang CY, Chen WY, Lai PY, Chung BC.
Mol Cell Endocrinol. 2013 May 22;371(1-2):148-53. doi: 10.1016/j.mce.2012.11.019. Epub 2012 Dec 5. (REVIEW)
PMID 23219870
 
The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1.
Wang W, Zhang C, Marimuthu A, Krupka HI, Tabrizizad M, Shelloe R, Mehra U, Eng K, Nguyen H, Settachatgul C, Powell B, Milburn MV, West BL.
Proc Natl Acad Sci U S A. 2005 May 24;102(21):7505-10. Epub 2005 May 16.
PMID 15897460
 
The Wilms tumor suppressor WT1 regulates early gonad development by activation of Sf1.
Wilhelm D, Englert C.
Genes Dev. 2002 Jul 15;16(14):1839-51.
PMID 12130543
 
The orphan receptors NGFI-B and steroidogenic factor 1 establish monomer binding as a third paradigm of nuclear receptor-DNA interaction.
Wilson TE, Fahrner TJ, Milbrandt J.
Mol Cell Biol. 1993 Sep;13(9):5794-804.
PMID 8395013
 
Cloning and sequence analysis of the human gene encoding steroidogenic factor 1.
Wong M, Ramayya MS, Chrousos GP, Driggers PH, Parker KL.
J Mol Endocrinol. 1996 Oct;17(2):139-47.
PMID 8938589
 
Functional characterization of a new human Ad4BP/SF-1 variation, G146A.
WuQiang F, Yanase T, Wei L, Oba K, Nomura M, Okabe T, Goto K, Nawata H.
Biochem Biophys Res Commun. 2003 Nov 28;311(4):987-94.
PMID 14623279
 
Transcriptional activation of steroidogenic factor-1 by hypomethylation of the 5' CpG island in endometriosis.
Xue Q, Lin Z, Yin P, Milad MP, Cheng YH, Confino E, Reierstad S, Bulun SE.
J Clin Endocrinol Metab. 2007 Aug;92(8):3261-7. Epub 2007 May 22.
PMID 17519303
 
Methylation of a novel CpG island of intron 1 is associated with steroidogenic factor 1 expression in endometriotic stromal cells.
Xue Q, Xu Y, Yang H, Zhang L, Shang J, Zeng C, Yin P, Bulun SE.
Reprod Sci. 2014 Mar;21(3):395-400. doi: 10.1177/1933719113497283. Epub 2013 Jul 30.
PMID 23899549
 
Liver receptor homolog-1 regulates the transcription of steroidogenic enzymes and induces the differentiation of mesenchymal stem cells into steroidogenic cells.
Yazawa T, Inanoka Y, Mizutani T, Kuribayashi M, Umezawa A, Miyamoto K.
Endocrinology. 2009 Aug;150(8):3885-93. doi: 10.1210/en.2008-1310. Epub 2009 Apr 9.
PMID 19359379
 
Differentiation of mesenchymal stem cells and embryonic stem cells into steroidogenic cells using steroidogenic factor-1 and liver receptor homolog-1.
Yazawa T, Kawabe S, Inaoka Y, Okada R, Mizutani T, Imamichi Y, Ju Y, Yamazaki Y, Usami Y, Kuribayashi M, Umezawa A, Miyamoto K.
Mol Cell Endocrinol. 2011 Apr 10;336(1-2):127-32. doi: 10.1016/j.mce.2010.11.025. Epub 2010 Dec 1.
PMID 21129436
 
Differentiation of adult stem cells derived from bone marrow stroma into Leydig or adrenocortical cells.
Yazawa T, Mizutani T, Yamada K, Kawata H, Sekiguchi T, Yoshino M, Kajitani T, Shou Z, Umezawa A, Miyamoto K.
Endocrinology. 2006 Sep;147(9):4104-11. Epub 2006 May 25.
PMID 16728492
 
Differential effects of high and low steroidogenic factor-1 expression on CYP11B2 expression and aldosterone production in adrenocortical cells.
Ye P, Nakamura Y, Lalli E, Rainey WE.
Endocrinology. 2009 Mar;150(3):1303-9. doi: 10.1210/en.2008-0667. Epub 2008 Oct 30.
PMID 18974272
 
Testicular differentiation factor SF-1 is required for human spleen development.
Zangen D, Kaufman Y, Banne E, Weinberg-Shukron A, Abulibdeh A, Garfinkel BP, Dweik D, Kanaan M, Camats N, Fluck C, Renbaum P, Levy-Lahad E.
J Clin Invest. 2014 May 1;124(5):2071-5. Epub 2014 Apr 8.
PMID 24905461
 
Steroidogenic factor 1 (SF1) is essential for pituitary gonadotrope function.
Zhao L, Bakke M, Krimkevich Y, Cushman LJ, Parlow AF, Camper SA, Parker KL.
Development. 2001 Jan;128(2):147-54.
PMID 11124111
 
Central nervous system-specific knockout of steroidogenic factor 1 results in increased anxiety-like behavior.
Zhao L, Kim KW, Ikeda Y, Anderson KK, Beck L, Chase S, Tobet SA, Parker KL.
Mol Endocrinol. 2008 Jun;22(6):1403-15. doi: 10.1210/me.2008-0034. Epub 2008 Mar 27.
PMID 18372344
 
Two-step regulation of Ad4BP/SF-1 gene transcription during fetal adrenal development: initiation by a Hox-Pbx1-Prep1 complex and maintenance via autoregulation by Ad4BP/SF-1.
Zubair M, Ishihara S, Oka S, Okumura K, Morohashi K.
Mol Cell Biol. 2006 Jun;26(11):4111-21.
PMID 16705164
 
Steroidogenic factor-1 contributes to the cyclic-adenosine monophosphate down-regulation of human SRY gene expression.
de Santa Barbara P, Mejean C, Moniot B, Malcles MH, Berta P, Boizet-Bonhoure B.
Biol Reprod. 2001 Mar;64(3):775-83.
PMID 11207191
 

Citation

This paper should be referenced as such :
Carmen Ruggiero, Mabrouka Doghman, Enzo Lalli
NR5A1 (nuclear receptor subfamily 5, group A, member 1)
Atlas Genet Cytogenet Oncol Haematol. 2015;19(8):522-534.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/NR5A1ID45858ch9q33.html


External links

Nomenclature
HGNC (Hugo)NR5A1   7983
Cards
AtlasNR5A1ID45858ch9q33
Entrez_Gene (NCBI)NR5A1  2516  nuclear receptor subfamily 5 group A member 1
AliasesAD4BP; ELP; FTZ1; FTZF1; 
POF7; SF-1; SF1; SPGF8; SRXY3; hSF-1
GeneCards (Weizmann)NR5A1
Ensembl hg19 (Hinxton)ENSG00000136931 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000136931 [Gene_View]  chr9:124481236-124507420 [Contig_View]  NR5A1 [Vega]
ICGC DataPortalENSG00000136931
TCGA cBioPortalNR5A1
AceView (NCBI)NR5A1
Genatlas (Paris)NR5A1
WikiGenes2516
SOURCE (Princeton)NR5A1
Genetics Home Reference (NIH)NR5A1
Genomic and cartography
GoldenPath hg38 (UCSC)NR5A1  -     chr9:124481236-124507420 -  9q33.3   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)NR5A1  -     9q33.3   [Description]    (hg19-Feb_2009)
EnsemblNR5A1 - 9q33.3 [CytoView hg19]  NR5A1 - 9q33.3 [CytoView hg38]
Mapping of homologs : NCBINR5A1 [Mapview hg19]  NR5A1 [Mapview hg38]
OMIM184757   612964   612965   613957   
Gene and transcription
Genbank (Entrez)AB307718 AK090858 BC032501 EU446475 HQ692856
RefSeq transcript (Entrez)NM_004959
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)NR5A1
Cluster EST : UnigeneHs.495108 [ NCBI ]
CGAP (NCI)Hs.495108
Alternative Splicing GalleryENSG00000136931
Gene ExpressionNR5A1 [ NCBI-GEO ]   NR5A1 [ EBI - ARRAY_EXPRESS ]   NR5A1 [ SEEK ]   NR5A1 [ MEM ]
Gene Expression Viewer (FireBrowse)NR5A1 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevestigatorExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)2516
GTEX Portal (Tissue expression)NR5A1
Human Protein AtlasENSG00000136931-NR5A1 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ13285   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ13285  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ13285
Splice isoforms : SwissVarQ13285
PhosPhoSitePlusQ13285
Domaine pattern : Prosite (Expaxy)NUCLEAR_REC_DBD_1 (PS00031)    NUCLEAR_REC_DBD_2 (PS51030)   
Domains : Interpro (EBI)NR5_fam    Nucl_hrmn_rcpt_lig-bd    Nuclear_hrmn_rcpt    Znf_hrmn_rcpt    Znf_NHR/GATA   
Domain families : Pfam (Sanger)Hormone_recep (PF00104)    zf-C4 (PF00105)   
Domain families : Pfam (NCBI)pfam00104    pfam00105   
Domain families : Smart (EMBL)HOLI (SM00430)  ZnF_C4 (SM00399)  
Conserved Domain (NCBI)NR5A1
DMDM Disease mutations2516
Blocks (Seattle)NR5A1
PDB (SRS)1YOW    1ZDT    4QJR    4QK4   
PDB (PDBSum)1YOW    1ZDT    4QJR    4QK4   
PDB (IMB)1YOW    1ZDT    4QJR    4QK4   
PDB (RSDB)1YOW    1ZDT    4QJR    4QK4   
Structural Biology KnowledgeBase1YOW    1ZDT    4QJR    4QK4   
SCOP (Structural Classification of Proteins)1YOW    1ZDT    4QJR    4QK4   
CATH (Classification of proteins structures)1YOW    1ZDT    4QJR    4QK4   
SuperfamilyQ13285
Human Protein Atlas [tissue]ENSG00000136931-NR5A1 [tissue]
Peptide AtlasQ13285
HPRD01702
IPIIPI00012446   IPI00640780   IPI00644838   
Protein Interaction databases
DIP (DOE-UCLA)Q13285
IntAct (EBI)Q13285
FunCoupENSG00000136931
BioGRIDNR5A1
STRING (EMBL)NR5A1
ZODIACNR5A1
Ontologies - Pathways
QuickGOQ13285
Ontology : AmiGORNA polymerase II regulatory region sequence-specific DNA binding  RNA polymerase II distal enhancer sequence-specific DNA binding  luteinization  DNA binding  chromatin binding  chromatin binding  transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding  steroid hormone receptor activity  transcription coactivator activity  RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding  protein binding  phospholipid binding  nucleus  nucleoplasm  transcription initiation from RNA polymerase II promoter  cell-cell signaling  sex determination  primary sex determination  zinc ion binding  male gonad development  female gonad development  hormone-mediated signaling pathway  tissue development  multicellular organism aging  positive regulation of gene expression  positive regulation of gene expression  enzyme binding  cell differentiation  adrenal gland development  intracellular receptor signaling pathway  hormone metabolic process  steroid hormone mediated signaling pathway  sequence-specific DNA binding  positive regulation of transcription from RNA polymerase II promoter  positive regulation of transcription from RNA polymerase II promoter  positive regulation of transcription from RNA polymerase II promoter  regulation of steroid biosynthetic process  maintenance of protein location in nucleus  RNA polymerase II transcription factor complex  RNA polymerase II transcription factor complex  positive regulation of male gonad development  negative regulation of female gonad development  
Ontology : EGO-EBIRNA polymerase II regulatory region sequence-specific DNA binding  RNA polymerase II distal enhancer sequence-specific DNA binding  luteinization  DNA binding  chromatin binding  chromatin binding  transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding  steroid hormone receptor activity  transcription coactivator activity  RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding  protein binding  phospholipid binding  nucleus  nucleoplasm  transcription initiation from RNA polymerase II promoter  cell-cell signaling  sex determination  primary sex determination  zinc ion binding  male gonad development  female gonad development  hormone-mediated signaling pathway  tissue development  multicellular organism aging  positive regulation of gene expression  positive regulation of gene expression  enzyme binding  cell differentiation  adrenal gland development  intracellular receptor signaling pathway  hormone metabolic process  steroid hormone mediated signaling pathway  sequence-specific DNA binding  positive regulation of transcription from RNA polymerase II promoter  positive regulation of transcription from RNA polymerase II promoter  positive regulation of transcription from RNA polymerase II promoter  regulation of steroid biosynthetic process  maintenance of protein location in nucleus  RNA polymerase II transcription factor complex  RNA polymerase II transcription factor complex  posItive0rågulation of male gonad development  negative regulation of female gonad development  
REACTOMEQ13285 [protein]
REACTOME PathwaysR-HSA-452723 [pathway]   
NDEx NetworkNR5A1
Atlas of Cancer Signalling NetworkNR5A1
Wikipedia pathwaysNR5A1
Orthology - Evolution
OrthoDB2516
GeneTree (enSembl)ENSG00000136931
Phylogenetic Trees/Animal Genes : TreeFamNR5A1
HOVERGENQ13285
HOGENOMQ13285
Homologs : HomoloGeneNR5A1
Homology/Alignments : Family Browser (UCSC)NR5A1
Gene fusions - Rearrangements
Tumor Fusion PortalNR5A1
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerNR5A1 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)NR5A1
dbVarNR5A1
ClinVarNR5A1
1000_GenomesNR5A1 
Exome Variant ServerNR5A1
ExAC (Exome Aggregation Consortium)ENSG00000136931
GNOMAD BrowserENSG00000136931
Genetic variants : HAPMAP2516
Genomic Variants (DGV)NR5A1 [DGVbeta]
DECIPHERNR5A1 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisNR5A1 
Mutations
ICGC Data PortalNR5A1 
TCGA Data PortalNR5A1 
Broad Tumor PortalNR5A1
OASIS PortalNR5A1 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICNR5A1  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDNR5A1
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
LOVD (Leiden Open Variation Database)Mendelian genes
BioMutasearch NR5A1
DgiDB (Drug Gene Interaction Database)NR5A1
DoCM (Curated mutations)NR5A1 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)NR5A1 (select a term)
intoGenNR5A1
NCG5 (London)NR5A1
Cancer3DNR5A1(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM184757    612964    612965    613957   
Orphanet1011    1044    19642    22774   
DisGeNETNR5A1
MedgenNR5A1
Genetic Testing Registry NR5A1
NextProtQ13285 [Medical]
TSGene2516
GENETestsNR5A1
Target ValidationNR5A1
Huge Navigator NR5A1 [HugePedia]
snp3D : Map Gene to Disease2516
BioCentury BCIQNR5A1
ClinGenNR5A1 (curated)
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD2516
Chemical/Pharm GKB GenePA31764
Clinical trialNR5A1
Miscellaneous
canSAR (ICR)NR5A1 (select the gene name)
Probes
Litterature
PubMed222 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineNR5A1
EVEXNR5A1
GoPubMedNR5A1
iHOPNR5A1
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Nov 21 14:57:58 CET 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.